

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSI SERVER PATERTS AND TRACEMARKS Washington 12 (2013) where regarded which

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO	
09 750,456	12 28 2000	Glenn Friedrich	LEX-0286-USA	6630	
75	12 17 2002				
Lance K. Ishimoto			EXAMINER		
Lexicon Genetic 4000 Research	Forest Drive		FALK, ANN	NNE MARIE	
The Woodlands, TX 77381			ARTUNIT	PAPER NUMBER	
			1632	1	
			DATE MAILED: 12 17 2002	/	

Please find below and/or attached an Office communication concerning this application or proceeding.

File

	Application No.	Applicant(s)			
	09/750,456	FRIEDRICH ET AL.			
Office Action Summary	Examiner	Art Unit			
	Anne-Marie Falk, Ph.D.	1632			
The MAILING DATE of this communication appeared for Reply	ears on the cover sheet w	ith the correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	6(a). In no event, however, may a within the statutory minimum of thi apply and will expire SIX (6) MO cause the application to become A	reply be timely filed rty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).			
1) Responsive to communication(s) filed on	<u> </u>				
2a) ☐ This action is FINAL . 2b) ☑ Thi	s action is non-final.				
3) Since this application is in condition for allowa closed in accordance with the practice under EDisposition of Claims					
4) Claim(s) 1-7 is/are pending in the application.					
4a) Of the above claim(s) is/are withdraw	n from consideration.				
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) <u>1-7</u> are subject to restriction and/or ele	ection requirement.				
Application Papers					
9) The specification is objected to by the Examiner					
10) The drawing(s) filed on is/are: a) accept	ted or b) objected to by	the Examiner.			
Applicant may not request that any objection to the	•				
11) The proposed drawing correction filed on		disapproved by the Examiner.			
If approved, corrected drawings are required in rep					
12) The oath or declaration is objected to by the Exa	iminer.				
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C.	§ 119(a)-(d) or (t).			
a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priori application from the International Bur * See the attached detailed Office action for a list of 	eau (PCT Rule 17.2(a)).				
14) Acknowledgment is made of a claim for domestic	priority under 35 U.S.C	§ 119(e) (to a provisional application).			
a) The translation of the foreign language prov 15) Acknowledgment is made of a claim for domestic	• •				
Attachment(s)					
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 	5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)			
S Patent and Trademark Office					

DETAILED ACTION

Claims 1-7 are pending in the instant application.

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

Group 1, Claims 1-7, drawn to cells comprising a mutation in a gene comprising the nucleotide sequence set forth in SEQ ID NO: 1, classified in class 435, subclass 354.

Groups 2-890, Claims 1-7, drawn to cells comprising a mutation in a gene comprising the nucleotide sequence set forth in SEQ ID NO: 2-890, respectively, classified in class 435, subclass 354.

Group 891, Claims 1-7, drawn to cells comprising a mutation in a gene comprising the nucleotide sequence set forth in SEQ ID NO: 891, classified in class 435, subclass 354.

The inventions are distinct, each from the other because of the following reasons:

Polynucleotides of different nucleotide sequence are structurally distinct chemical compounds. Such polynucleotides and compositions comprising them are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121 and therefore subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq. The polynucleotides are not obvious, one over the other. Accordingly, only one independent and distinct nucleotide sequence (or compositions comprising the nucleotide sequence) will be examined in a single application.

Application/Control Number: 09/750,456

Art Unit: 1632

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their recognized divergent subject matter and because the searches required for the separate inventions are not coextensive, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne-Marie Falk whose telephone number is (703) 306-9155. The examiner can normally be reached Monday through Thursday and alternate Fridays from 10:00 AM to 7:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached on (703) 305-4051. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the patent analyst, Tiffiany Tabb, whose telephone number is (703) 305-1238.

Anne-Marie Falk, Ph.D.

Anne-Marie Falk
ANNE-MARIE BAKER
PATENT EXAMINER